SPHERE Study for Hypereosinophilic Syndrome
A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.
- Sex: Any
- Age: Child (Birth - 17)
- Accepting Healthy People: No
- Type: Interventional / Device
- Trial Phase: Phase III
- Conditions Being Studied: Hypereosinophilic Syndrome
Study Purpose
The purpose of this study is to learn more about Hypereosinophilic syndrome (HES) and to test the efficacy and safety of an investigational drug, mepolizumab on children (aged 6 to 11 years) and teenagers (aged 12 to 17 years) who have and are being treated for HES. This medication is already FDA- approved for children and adults ages 12 and up with HES.
Who Can Participate
Participants between the ages of 6 and 17 years of age diagnosed with Hypereosinophilic Syndrome may be eligible for this study.
Locations
UH Rainbow Babies & Children's
2101 Adelbert Road
Cleveland OH, 44106
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001509
- StudyID: 2021-0652
- ClinicalTrials.gov: NCT04965636
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422